Inside the FDA: Reflections from Dr. Wiley Chambers on Ophthalmic Drug Development
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Inside the FDA: Reflections from Dr. Wiley Chambers on Ophthalmic Drug Development
-
ナレーター：
-
著者：
このコンテンツについて
In this week’s episode of the BroadEYE Podcast, hosts Dr. Shawn Maloney and Dr. Carlos Quezada-Ruiz sit down with Dr. Wiley Chambers, recently retired Deputy Director of the Division of Ophthalmology at the U.S. Food and Drug Administration (FDA). With over 36 years at the FDA, Dr. Chambers offers a rare insider’s perspective on regulatory science, ophthalmic drug development, and the evolution of clinical trial oversight.
This episode explores:
- How ophthalmology regulation has changed over the decades
- Common pitfalls in pre-IND meetings and what smart innovators do differently
- Lessons learned from reviewing countless drug and biologic applications
- The future of FDA guidance in areas like rare disease, gene therapy, and digital endpoints
Dr. Chambers also shares personal reflections on mentorship, scientific integrity, and his transition out of federal service after a distinguished career.
About Our Guest Dr. Wiley Chambers served as a lead ophthalmic reviewer at the U.S. FDA from 1987 until his retirement in 2023. As Deputy Director of the Division of Ophthal